Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0524 to Improve Tolerability of Extended Release Niacin
NCT00376584Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2006
- Primary completion
- Jan 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of laropiprant in hypercholesterolemia and hyperlipidemia (3 arms), sponsored by Merck & Co. Primary endpoint: Global Flushing Severity Score at 7 days. Started Jul 2006; status: completed.
02
Drugs
laropiprant
03
Conditions
hypercholesterolemiahyperlipidemia
Beyond the preview
Go deeper on NCT00376584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376584.